Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
Thompson-Coon, Jo; Liu, Z; Hoyle, M; et al.Rogers, G; Green, C; Moxham, T; Welch, K; Stein, Ken
Date: 21 July 2009
Journal
British Journal of Cancer
Publisher
Cancer Research UK
Publisher DOI
Related links
Abstract
Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-alpha (IFN-alpha)) in the treatment of advanced metastatic RCC.
Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-alpha (IFN-alpha)) in the treatment of advanced metastatic RCC.
Institute of Health Research
Collections of Former Colleges
Item views 0
Full item downloads 0